Nyxoah S.A. (NASDAQ:NYXH)

Nyxoah S.A. NYXH

Healthcare - Medical - Instruments & Supplies - NASDAQ - BE

Watchlist

$ 9.94

-0.996 %

$ 342 M

Market Cap

-5.49

P/E

1. INTRINSIC VALUE

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one NYXH stock under the worst case scenario is HIDDEN Compared to the current market price of 9.94 USD, Nyxoah S.A. is HIDDEN

NYXH Intrinsic Value
HIDDEN

SHOW

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one NYXH stock under the base case scenario is HIDDEN Compared to the current market price of 9.94 USD, Nyxoah S.A. is HIDDEN

NYXH Intrinsic Value
HIDDEN

SHOW

This DCF valuation model was last updated on Mar, 3, 2025.

The intrinsic value of one NYXH stock under the best case scenario is HIDDEN Compared to the current market price of 9.94 USD, Nyxoah S.A. is HIDDEN

NYXH Intrinsic Value
HIDDEN

SHOW

2. FUNDAMENTAL ANALYSIS

Price Chart NYXH

FINANCIALS

Annual
Quarterly

-45.1 M OPERATING INCOME

-44.8 M OPERATING CASH FLOW

32 M INVESTING CASH FLOW

16.9 M FINANCING CASH FLOW

-15 M OPERATING INCOME

-11.3 M OPERATING CASH FLOW

-28.2 M INVESTING CASH FLOW

45.2 M FINANCING CASH FLOW

Balance Sheet Nyxoah S.A.

124 M ASSETS
26.1 M LIABILITIES

Current Assets	68.4 M
Cash & Short-Term Investments	57.7 M
Receivables	2.76 M
Other Current Assets	7.84 M
Non-Current Assets	55.8 M
Long-Term Investments	0
PP&E	7.98 M
Other Non-Current Assets	47.8 M

Current Liabilities	14.4 M
Accounts Payable	4.1 M
Short-Term Debt	1.22 M
Other Current Liabilities	9.13 M
Non-Current Liabilities	11.7 M
Long-Term Debt	11.5 M
Other Non-Current Liabilities	203 K

EFFICIENCY

Earnings Waterfall Nyxoah S.A.

Revenue	4.35 M
Cost Of Revenue	1.66 M
Gross Profit	2.69 M
Operating Expenses	47.8 M
Operating Income	-45.1 M
Other Expenses	-445 K
Net Income	-44.7 M

RATIOS

-1037.30% OPERATING MARGIN

FREE CASH FLOW ANALYSIS

Free Cash Flow Analysis Nyxoah S.A.

Net Income	-44.7 M
Depreciation & Amortization	2.36 M
Capital Expenditures	-11 M
Stock-Based Compensation	2.61 M
Change in Working Capital	-3.49 M
Others	-1.6 M
Free Cash Flow	-55.7 M

3. WALL STREET ANALYSTS ESTIMATES

Wall Street Analysts Price Targets Nyxoah S.A.

Wall Street analysts predict an average 1-year price target for NYXH of $19 , with forecasts ranging from a low of $15 to a high of $27 .

NYXH Lowest Price Target Wall Street Target

15 USD 50.91%

NYXH Average Price Target Wall Street Target

19 USD 91.15%

NYXH Highest Price Target Wall Street Target

27 USD 171.63%

4. DIVIDEND ANALYSIS

NYXH does not distribute dividends.

5. COMPETITION

Pro-Dex, Inc. designs, develops, and manufactures powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

66.8 USD

PDEX

Undervalued 75.79%

KORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally.

-17.7 USD

KRMD

Overvalued 614.64%

NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics.

-82.2 USD

NXGL

Overvalued 2940.48%

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.

-111 USD

DXR

Overvalued 1531.79%

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide.

50.3 USD

LMAT

Overvalued 46.26%

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.

140 USD

UTMD

Undervalued 136.65%

Merit Medical Systems, Inc. designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures, primarily in cardiology, radiology, oncology, critical care, and endoscopy.

53 USD

MMSI

Overvalued 49.57%

AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally.

14.5 USD

ATRC

Overvalued 63.44%

6. Ownership

Insider Ownership Nyxoah S.A.

Summary
Transactions

Sold

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

0 USD 0

Bought

0 USD 0

0-3 MONTHS

0 USD 0

3-6 MONTHS

0 USD 0

6-9 MONTHS

0 USD 0

9-12 MONTHS

Date	Value	Insider	Amount	Avg Price

7. News

Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East Nyxoah Announces Commercial Launch of Genio® Breakthrough Therapy in the Middle East First patient implanted with Genio at Saudi German Hospital in Dubai, United Arab Emirates globenewswire.com - 1 week ago

Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), January 20, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On January 16, 2025, Nyxoah received a transparency notification from BlackRock, Inc. and related persons. globenewswire.com - 1 month ago

Nyxoah: The Future Of OSA Nyxoah's Genio implant is poised to revolutionize Obstructive Sleep Apnea treatment, with FDA approval expected in Q1 2025 acting as a potential catalyst for shares. Nyxoah, founded by Robert Taub, is led by Olivier Taelman and focuses on the Genio implant, which offers a less intrusive alternative to CPAP and Inspire Therapy. Despite a high burn rate, Nyxoah has sufficient cash reserves to last until 2026, with U.S. market entry expected to significantly boost revenue post-FDA approval. seekingalpha.com - 2 months ago

Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), December 20, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On December 19, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons. globenewswire.com - 2 months ago

Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England Nyxoah Announces Commercial Launch of Genio® Innovative Therapy in England First patients implanted with Genio at UCLH, London globenewswire.com - 2 months ago

Nyxoah to Participate in the Piper Sandler 36th Annual Healthcare Conference Nyxoah to Participate in the Piper Sandler 36 th Annual Healthcare Conference globenewswire.com - 3 months ago

Invitation to attend the special shareholders' meeting of the Company to be held on December 19, 2024 REGULATED INFORMATION November 19, 2024, 7:00am CET / 1:00am ET NYXOAH SA (Euronext Brussels/Nasdaq: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the “Company”) Invitation to attend the special shareholders' meeting of the Company to be held on December 19, 2024 The board of directors of the Company is pleased to invite its securities holders to attend the special shareholders' meeting of the Company, to be held on Thursday, December 19, 2024 at 3:00 p.m. CET at the Company's seat, or at such other place as will be indicated prior to such time. globenewswire.com - 3 months ago

Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), November 18, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On November 15, 2024, Nyxoah received a transparency notification from ResMed Inc. following the passive crossing of a threshold. globenewswire.com - 3 months ago

Nyxoah S.A. (NYXH) Q3 2024 Earnings Call Transcript Nyxoah S.A. (NASDAQ:NYXH ) Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications and IR Manager Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Adam Maeder - Piper Sandler Joe Federico - Stifel Suraj Kalia - Oppenheimer Ross Osborn - Cantor Fitzgerald David Rescott - Baird Operator Good day. seekingalpha.com - 3 months ago

Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates Nyxoah SA (NYXH) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.29 per share a year ago. zacks.com - 3 months ago

Nyxoah Appoints John Landry as Chief Financial Officer Nyxoah Appoints John Landry as Chief Financial Officer Current CFO, Loïc Moreau, to Transition into Role of President International Mont-Saint-Guibert, Belgium – November 4, 2024, 10:45pm CET / 4:45pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced the appointment of John Landry as Chief Financial Officer (CFO), effective November 4, 2024. This strategic appointment, in combination with the recent move to the United States of CEO Olivier Taelman, strengthens the Company's focus on the U.S. market. globenewswire.com - 3 months ago

8. Profile Summary

Nyxoah S.A. NYXH

COUNTRY BE

INDUSTRY Medical - Instruments & Supplies

MARKET CAP $ 342 M

Dividend Yield 0.00%

Description Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Contact Rue Edouard Belin 12, Mont-Saint-Guibert, 1435 https://www.nyxoah.com

IPO Date April 28, 2021

Employees 146

Officers Mr. Robert Taub MBA Co-Founder & Chairman Mr. Loic Moreau President of International Mr. Bruno Onkelinx Chief Operations Officer Mikaela Kirkwood Corporate Communication & Investor Relations Manager Ms. Maggie McGowan Chief HR Officer Mr. John Landry Chief Financial Officer Mr. Olivier Taelman Chief Executive Officer & Executive Director Mr. Jeyakumar Subbaroyan Chief Clinical Officer Ms. An Moonen General Counsel Mr. Remi Renard Chief of Staff

Price Chart NYXH

Nyxoah S.A. NYXH

Free

Unlimited Plan

Premium Plan